Pharma Costs: Indian Maker Sees Profit Jump Despite Rising Input Prices

Indian pharmaceutical company Granules India reported a sharp increase in earnings on Monday, showing that revenue growth can outpace rising production costs. The company's consolidated net profit for the quarter ended September 30 reached 1.82 billion rupees, or $19.19 million. This figure compares to 1.31 billion rupees during the same period last year.

Total revenue from operations climbed 20.3% to 15.60 billion rupees. Demand from North America drove this growth, accounting for 72% of total revenue. However, total expenses also increased by 18.5%, with the cost of materials consumed jumping 23.2%. These higher input costs put pressure on margins even as sales volumes rose.

Prasad Chigurupati, chairman and managing director, addressed the cost environment in a statement. He said, "Cost pressures will persist, and we are working with customers to manage them with a lag." The company relies on a global supply chain to distribute its products, maintaining operations across multiple continents to serve its international base.

Granules India operates ten manufacturing plants worldwide. Seven of these facilities are located in India, two are in the United States, and one is in Europe. The firm serves more than 80 countries and produces approximately one-third of the world's paracetamol supply. Analysts had previously looked to newer product lines and US approvals as key drivers for sales, a strategy that appears to have delivered results in the latest quarter.